According to the research report titled ‘Biosimilars Market Size By Product (Recombinant Non-Glycosylated Proteins {Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Interferon}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Follitropin, Low Molecular Weight Heparin}), By Application (Haematology {Neutropenia, Anaemia}, Oncology {Lung Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Leukaemia or Blood Cancer}, Autoimmune Disease {Arthritis, Inflammatory Bowel Disease, Psoriasis}, Growth Hormone Deficiency, Diabetes), By Manufacturer (Contract Research and Manufacturing Services, In-house), By Technology (Recombinant DNA Technology, Monoclonal Antibodies Technology) Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 - 2025,’ available with MarketStudyReport, the global biosimilars market is estimated to exceed USD 69 billion in valuation by 2025.

Focus towards improving public health issues, high occurrence of chronic conditions, rising R&D activities, and increasing demand for biosimilar drugs owing to their affordable nature are some of the major factors boosting global biosimilars market growth.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/2057053/  

Based on product landscape, The recombinant non-glycosylated proteins segment is estimated to expand at around 26.1% CAGR  over the estimation period owing to technological breakthroughs, rising development of insulin glargine, and growing demand of filgrastim.

Moving on to the application terrain, the report cites that haematology segment reached a valuation of USD 4,552.1 million in 2018 and is likely to showcase similar growth trends in the forthcoming years, on account of increasing number of people suffering from blood disorders such as anaemia and neutropenia, further boosting the sales of biosimilars across the globe.

By manufacturer, in-house manufacturing segment captured 75% market share in 2018 and is expected to witness 26.5% CAGR over the projection period owing to its cost reduction during delivery & shipping processes and increasing financial & operational capabilities of various companies.

In terms of the technology type, the recombinant DNA technology segment held 80% share in global biosimilars market and is predicted to expand significantly during the analysis timeframe. rDNA technology is known to improve biosimilar capabilities to treat various ailment immediately and efficiently.

Considering the geographical landscape, U.S. biosimilars market is estimated to witness 38.1% CAGR during the forecast timeline, primarily attributed to the availability of state-of-art biosimilar production facilities, technological breakthroughs, and high concentration of leading pharma companies.  

Elaborating on the competitive terrain, the major companies operating in global biosimilars marketplace are 3SBio Inc., Biocon Limited, C.H. Boehringer Sohn AG & Ko. KG, Coherus BioSciences Inc., Eli Lilly and Company, Lupin Limited, Novartis International AG, Samsung Bioepis Co. Ltd., Stada Arzneimittel AG, Wockhardt Ltd., Amgen Inc., Biogen Inc., Celltrion Inc., Dr. Reddy's Laboratories, Intas Pharmaceuticals Limited, Merck & Co. Inc., Ratiopharm Group, Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Zydus Lifesciences Limited.